Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

BUY
$182.66 - $235.53 $199,099 - $256,727
1,090 New
1,090 $218,000
Q3 2022

Nov 03, 2022

BUY
$138.54 - $232.0 $157,242 - $263,320
1,135 New
1,135 $227,000
Q4 2020

Feb 16, 2021

SELL
$122.97 - $147.0 $4.66 Million - $5.57 Million
-37,922 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$121.19 - $165.49 $4.34 Million - $5.93 Million
35,850 Added 1730.21%
37,922 $5.52 Million
Q2 2020

Aug 13, 2020

BUY
$104.21 - $156.44 $215,923 - $324,143
2,072 New
2,072 $307,000
Q3 2018

Nov 13, 2018

SELL
$87.52 - $122.67 $204,446 - $286,557
-2,336 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$88.31 - $107.8 $206,292 - $251,820
2,336 New
2,336 $230,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.